Ann: Midkine Ischemia Patent Allowed in US , page-15

Someone suggested I look at what SIR did today re a new nickel find. Up nearly 700% so that is where all the trader interest was today. SIR will retrace ST regardless of where the LT fundumentals sit IMHO because traders will always take profits. That may partly answer the lack of market response to CDY's patent which is as real as anything.

As posted, the trick for CDY should be to minimise post spike dumps. Me thinks & suspects that Evolis (while perhaps not the biggest potential iron in CDY's fire at the moment) could do this. With some positive sales results medium to long term retail investors may see this product as something real, tangibile and visible with revenue posted in each quarterly. They may not need to understand much about midkine , scientific explanations or clinical trial processes to feel something confident about the company.

Cheers